207 related articles for article (PubMed ID: 14576850)
1. Resistance to antifolates.
Zhao R; Goldman ID
Oncogene; 2003 Oct; 22(47):7431-57. PubMed ID: 14576850
[TBL] [Abstract][Full Text] [Related]
2. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Assaraf YG
Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates.
Sierra EE; Goldman ID
Semin Oncol; 1999 Apr; 26(2 Suppl 6):11-23. PubMed ID: 10598550
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment.
Hooijberg JH; de Vries NA; Kaspers GJ; Pieters R; Jansen G; Peters GJ
Cancer Chemother Pharmacol; 2006 Jul; 58(1):1-12. PubMed ID: 16362298
[TBL] [Abstract][Full Text] [Related]
6. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.
Shafran A; Ifergan I; Bram E; Jansen G; Kathmann I; Peters GJ; Robey RW; Bates SE; Assaraf YG
Cancer Res; 2005 Sep; 65(18):8414-22. PubMed ID: 16166320
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells.
Fotoohi AK; Albertioni F
Leuk Lymphoma; 2008 Mar; 49(3):410-26. PubMed ID: 18297517
[TBL] [Abstract][Full Text] [Related]
8. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
[TBL] [Abstract][Full Text] [Related]
9. The impact of folate status on the efficacy of colorectal cancer treatment.
Porcelli L; Assaraf YG; Azzariti A; Paradiso A; Jansen G; Peters GJ
Curr Drug Metab; 2011 Dec; 12(10):975-84. PubMed ID: 21787267
[TBL] [Abstract][Full Text] [Related]
10. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.
Gonen N; Assaraf YG
Drug Resist Updat; 2012 Aug; 15(4):183-210. PubMed ID: 22921318
[TBL] [Abstract][Full Text] [Related]
11. The antifolates.
Visentin M; Zhao R; Goldman ID
Hematol Oncol Clin North Am; 2012 Jun; 26(3):629-48, ix. PubMed ID: 22520983
[TBL] [Abstract][Full Text] [Related]
12. Cellular aspects of folate and antifolate membrane transport.
Brzezińska A; Wińska P; Balińska M
Acta Biochim Pol; 2000; 47(3):735-49. PubMed ID: 11310973
[TBL] [Abstract][Full Text] [Related]
13. Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate.
Pinard MF; Jolivet J; Ratnam M; Kathmann I; Molthoff C; Westerhof R; Schornagel JH; Jansen G
Cancer Chemother Pharmacol; 1996; 38(3):281-8. PubMed ID: 8646804
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies targeting proteins that regulate folate and reduced folate transport.
Trippett TM; Bertino JR
J Chemother; 1999 Feb; 11(1):3-10. PubMed ID: 10078775
[TBL] [Abstract][Full Text] [Related]
15. Altered transport of folic acid and antifolates through the carrier mediated reduced folate transport system in a human leukemia cell line resistant to (6R) 5,10-dideazatetrahydrofolic acid (DDATHF).
Pavlovic M; Leffert JJ; Russello O; Bunni MA; Beardsley GP; Priest DG; Pizzorno G
Adv Exp Med Biol; 1993; 338():775-8. PubMed ID: 8304227
[No Abstract] [Full Text] [Related]
16. The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs.
Goldman ID; Chattopadhyay S; Zhao R; Moran R
Curr Opin Investig Drugs; 2010 Dec; 11(12):1409-23. PubMed ID: 21154123
[TBL] [Abstract][Full Text] [Related]
17. Membrane transport of folates.
Matherly LH; Goldman DI
Vitam Horm; 2003; 66():403-56. PubMed ID: 12852262
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
[TBL] [Abstract][Full Text] [Related]
19. Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier.
Zhao R; Chattopadhyay S; Hanscom M; Goldman ID
Clin Cancer Res; 2004 Dec; 10(24):8735-42. PubMed ID: 15623659
[TBL] [Abstract][Full Text] [Related]
20. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
